Quantum Leap Healthcare Collaborative
search
Agents & Results

Agent Information

The I-SPY Program is committed to open science, through timely publication and release of results, and ultimately data, from all arms of our trials.
Close
Close
I-SPY Trial Manuscript
Close
Close
Close
Close
I-SPY People
Close
Close
<- Back to All Agents

mk2206

Trade Name:
Company:
Merck
Status:
Graduated
Agent Chaperone(s):
Jo ChienDebu Tripathy
Treatment Protocol:
MK-2206 is an Allosteric AKT Inhibitor. MK-2206 was administered orally at 135mg weekly (q1w) with Paclitaxel at 80 mg/m2 weekly (q1w) for 12 weeks. This regimen was followed by AC (q2w or q3w) for 4 weeks.
Date Entered I-SPY:
September 15, 2012
Date Left I-SPY:
May 14, 2014
No. Participants in Arm:
94
Graduating Subtypes:
HR-, HER2+ and HR-HER2+
Agent Description:

MK2206 is an orally available, allosteric small-molecule inhibitor of AKT, In pre-clinical models, MK-2206 was shown to bind to and inhibit the activity of AKT in a non-ATP competitive manner, which may result in the inhibition of the PI3K/AKT signaling pathway. MK-2206 can inhibit tumor cell proliferation and induce apoptosis (cell death) in some of those models.

Notes:
Final pCR Probabilities:
Primary Manuscript:
, 
. 
 
: 
, 
. 
abstractpdfdoi link

The I-SPY Trials

Sponsored by Quantum Leap Healthcare Collaborative™, a 501C(3) charitable organization accelerating the union of high-impact clinical research and patient care to improve and save lives.

 
Quick Links:
Media CenterCareersInvestigator Login
© 2019  Quantum Leap Healthcare Collaborative